The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer

The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer

Background: Tamoxifen is an effective treatment for primary breast cancer but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins, including antithrombin (AT), protein C (PC) and tissue factor (TF) pathway inhibitor, and enhances thrombin generation (TG). Howeve...

Full description

Bibliographic Details
Main Authors: Sanne M. Buijs, Daan C.H. van Dorst, Marieke J.H.A. Kruip, Rob F.P. van den Akker, Ka L. Cheung, Robert Porrazzo, Esther Oomen-de Hoop, Agnes Jager, Stijn L.W. Koolen, Jorie Versmissen, A.H. Jan Danser, Henri H. Versteeg, Mettine H.A. Bos, Ron H.J. Mathijssen
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Tamoxifen
Endoxifen
Venous thromboembolism
Breast neoplasms
Therapeutic drug monitoring
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223017675

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223017675

Similar Items